Alzheimer’s disease (AD), the most prevalent neurodegenerative disorder, continues to pose significant challenges despite advances in anti-amyloid therapies. New research from Harvard Medical School and Washington University School of Medicine, published in Science Translational Medicine, has unveiled a novel therapeutic approach: the use of inhaled xenon gas to modulate microglia and ameliorate disease progression in mouse models of AD.

How Xenon Targets Microglia

Microglia, the brain’s resident immune cells, play a dual role in neurodegeneration. While they can clear amyloid-beta (Aβ) plaques and damaged neurons, chronic activation leads to neuroinflammation, contributing to disease progression. Xenon gas, an inert anaesthetic, penetrates the blood-brain barrier and appears to modulate microglia to adopt a “pre-neurodegenerative microglia” (pre-MGnD) state.